BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35731991)

  • 21. T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
    Esparragosa Vazquez I; Ndiaye M; Di Stefano AL; Younan N; Larrieu-Ciron D; Seyve A; Picart T; Meyronet D; Boutet C; Vassal F; Carpentier C; Figarella-Branger D; Dehais C; Forest F; Rivoirard R; Ducray F;
    Eur J Neurol; 2023 Sep; 30(9):2879-2883. PubMed ID: 37204066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
    Zander T; Nettekoven W; Kraus JA; Pels H; Ko YD; Vetter H; Klockgether T; Schlegel U
    J Neurol; 2002 Aug; 249(8):1055-7. PubMed ID: 12195453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
    Shaw EG; Wang M; Coons SW; Brachman DG; Buckner JC; Stelzer KJ; Barger GR; Brown PD; Gilbert MR; Mehta MP
    J Clin Oncol; 2012 Sep; 30(25):3065-70. PubMed ID: 22851558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
    Gonzalez-Aguilar A; Reyes-Moreno I; Peiro-Osuna RP; Hernandez-Hernandez A; Gutierrez-Aceves A; Santos-Zambrano J; Guerrero-Juarez V; Lopez-Martinez M; Castro-Martinez E
    Rev Neurol; 2018 Oct; 67(8):293-297. PubMed ID: 30289152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
    Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
    J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
    van den Bent MJ
    Am Soc Clin Oncol Educ Book; 2013; ():114-6. PubMed ID: 23714473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
    van den Bent MJ
    Neuro Oncol; 2014 Dec; 16(12):1570-4. PubMed ID: 25355680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
    Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD
    Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.
    Vesper J; Graf E; Wille C; Tilgner J; Trippel M; Nikkhah G; Ostertag C
    BMC Neurol; 2009 Jul; 9():33. PubMed ID: 19604414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
    Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
    Streffer J; Schabet M; Bamberg M; Grote EH; Meyermann R; Voigt K; Dichgans J; Weller M
    J Neurol; 2000 Apr; 247(4):297-302. PubMed ID: 10836623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
    Keogh RJ; Aslam R; Hennessy MA; Coyne Z; Hennessy BT; Breathnach OS; Grogan L; Morris PG
    BMC Cancer; 2021 Feb; 21(1):140. PubMed ID: 33557783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas.
    Kim L; Hochberg FH; Thornton AF; Harsh GR; Patel H; Finkelstein D; Louis DN
    J Neurosurg; 1996 Oct; 85(4):602-7. PubMed ID: 8814163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
    Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
    J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
    Macdonald DR; Gaspar LE; Cairncross JG
    Ann Neurol; 1990 May; 27(5):573-4. PubMed ID: 2360797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
    J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
    Prados MD; Scott C; Sandler H; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1109-15. PubMed ID: 10613302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
    Lecavalier-Barsoum M; Quon H; Abdulkarim B
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007104. PubMed ID: 24833028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
    Cairncross G; Macdonald D; Ludwin S; Lee D; Cascino T; Buckner J; Fulton D; Dropcho E; Stewart D; Schold C
    J Clin Oncol; 1994 Oct; 12(10):2013-21. PubMed ID: 7931469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
    Bouffet E; Mornex F; Jouvet A; Thiesse P; Mertens P; Helfre S; Sindou M; Bret P
    Bull Cancer; 1997 Oct; 84(10):951-6. PubMed ID: 9435796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.